Drug intelligence / Profile preview

pyrimethamine + sulfadiazine

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Pyrimethamine + sulfadiazine is a combination antimicrobial therapy that works synergistically to treat parasitic infections, particularly toxoplasmosis. Pyrimethamine inhibits dihydrofolate reductase while sulfadiazine competes with p-aminobenzoic acid, both disrupting folate metabolism in parasites and preventing their DNA synthesis and reproduction. This combination is particularly effective against Toxoplasma gondii infections and is typically administered with folinic acid to reduce side effects.

Targets

DHFR-TS (Bifunctional dihydrofolate reductase-thymidylate synthase)DHPS (Dihydropteroate synthase)

Beyond the preview

Go deeper on pyrimethamine + sulfadiazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pyrimethamine + sulfadiazine.

Explore the full profile